Skip to content
2000
image of Comparative Therapeutic Efficacy of Lipid-Based Nanocarriers versus Traditional Treatments for Psoriasis: A Comprehensive Review

Abstract

Psoriasis is a chronic inflammatory skin condition with complex autoimmune and genetic origins, affecting approximately 125 million people globally, with prevalence rates ranging from 0.9% in the U.S. to 8.5% in Norway. This disease places a substantial economic burden on healthcare systems, with the average annual treatment cost per individual in the U.S. estimated at $2,528. Existing therapies often fall short due to issues like limited drug penetration and adverse effects, leading to patient dissatisfaction and treatment discontinuation. This review examines advancements in lipid-based nanocarriers for topical psoriasis management, highlighting their potential to overcome these therapeutic barriers. Lipid-based nanocarriers, including liposomes, niosomes, and Nanostructured Lipid Carriers (NLCs), enhance drug stability, controlled release, and targeted delivery, which are pivotal in improving therapeutic outcomes. Innovations in combinatorial lipid-based therapies show promise in preclinical and clinical studies, supporting enhanced efficacy and improved quality of life for psoriasis patients. Future research should focus on optimizing these carriers for greater precision alongside rigorous clinical evaluations to validate their safety and impact.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnm/10.2174/0124054615331155250128060527
2025-02-12
2025-11-16

  • From This Site

    /content/journals/cnm/10.2174/0124054615331155250128060527
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Rendon A. Schäkel K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 2019 20 6 1475 10.3390/ijms20061475 30909615
    [Google Scholar]
  2. Rapalli V.K. Singhvi G. Dubey S.K. Gupta G. Chellappan D.K. Dua K. Emerging landscape in psoriasis management: From topical application to targeting biomolecules. Biomed. Pharmacother. 2018 106 707 713 10.1016/j.biopha.2018.06.136 29990862
    [Google Scholar]
  3. Griffiths C.E.M. van der Walt J.M. Ashcroft D.M. The global state of psoriasis disease epidemiology: A workshop report. Br. J. Dermatol. 2017 177 1 e4 e7 10.1111/bjd.15610 28555722
    [Google Scholar]
  4. Bhutani T. Wong J.W. Bebo B.F. Armstrong A.W. Access to health care in patients with psoriasis and psoriatic arthritis: Data from national psoriasis Foundation survey panels. JAMA Dermatol. 2013 149 6 717 721 10.1001/jamadermatol.2013.133 23783152
    [Google Scholar]
  5. Galimova E.S. Akhmetova V.L. Khusnutdinova E.K. Molecular genetic basis of susceptibility to psoriasis. Russ. J. Genet. 2008 44 5 513 522 10.1134/S1022795408050025 18672792
    [Google Scholar]
  6. Jiang S. Hinchliffe T.E. Wu T. Biomarkers of an autoimmune skin disease: Psoriasis. Genomics Proteomics Bioinformatics 2015 13 4 224 233 10.1016/j.gpb.2015.04.002 26362816
    [Google Scholar]
  7. Kamiya K. Kishimoto M. Sugai J. Komine M. Ohtsuki M. Risk fac- tors for the development of psoriasis. Int. J. Mol. Sci. 2019 20 18 4347 10.3390/ijms20184347 31491865
    [Google Scholar]
  8. Gottlieb A.B. Dann F. Comorbidities in patients with psoriasis. Am. J. Med. 2009 122 12 1150.e1 1150.e9 10.1016/j.amjmed.2009.06.021 19958894
    [Google Scholar]
  9. Mabuchi T. Chang T.W. Quinter S. Hwang S.T. Chemokine receptors in the pathogenesis and therapy of psoriasis. J. Dermatol. Sci. 2012 65 1 4 11 10.1016/j.jdermsci.2011.11.007 22177422
    [Google Scholar]
  10. Lin X. Huang T. Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic. Res. 2016 50 6 585 595 10.3109/10715762.2016.1162301 27098416
    [Google Scholar]
  11. Gillard S.E. Finlay A.Y. Current management of psoriasis in the United Kingdom: Patterns of prescribing and resource use in primary care. Int. J. Clin. Pract. 2005 59 11 1260 1267 10.1111/j.1368‑5031.2005.00680.x 16236077
    [Google Scholar]
  12. Katare O. Raza K. Singh B. Dogra S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Indian J. Dermatol. Venereol. Leprol. 2010 76 6 612 621 10.4103/0378‑6323.72451 21079304
    [Google Scholar]
  13. Lowes M.A. Bowcock A.M. Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007 445 7130 866 873 10.1038/nature05663 17314973
    [Google Scholar]
  14. Harder J. Schröder J.M. Psoriatic scales: A promising source for the isolation of human skin-derived antimicrobial proteins. J. Leukoc. Biol. 2005 77 4 476 486 10.1189/jlb.0704409 15629886
    [Google Scholar]
  15. Zhou Q. Mrowietz U. Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic. Biol. Med. 2009 47 7 891 905 10.1016/j.freeradbiomed.2009.06.033 19577640
    [Google Scholar]
  16. Briganti S. Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What’s new. J. Eur. Acad. Dermatol. Venereol. 2003 17 6 663 669 10.1046/j.1468‑3083.2003.00751.x 14761133
    [Google Scholar]
  17. Rapp S.R. Feldman S.R. Exum M.L. Fleischer A.B. Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 1999 41 3 401 407 10.1016/S0190‑9622(99)70112‑X 10459113
    [Google Scholar]
  18. Voorhees A.S.V. Fried R. Depression and quality of life in psoriasis. Postgrad. Med. 2009 121 4 154 161 10.3810/pgm.2009.07.2040 19641281
    [Google Scholar]
  19. Gupta M.A. Gupta A.K. Psoriasis and sex: A study of moderately to severely affected patients. Int. J. Dermatol. 1997 36 4 259 262 10.1046/j.1365‑4362.1997.00032.x 9169321
    [Google Scholar]
  20. Krueger G. Koo J. Lebwohl M. Menter A. Stern R.S. Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 2001 137 3 280 284 11255325
    [Google Scholar]
  21. Yu A.P. Tang J. Xie J. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr. Med. Res. Opin. 2009 25 10 2429 2438 10.1185/03007990903185557 19663687
    [Google Scholar]
  22. García-Pérez M.E. Jean J. Pouliot R. Antipsoriatic drug development: Challenges and new emerging therapies. Recent Pat. Inflamm. Allergy Drug Discov. 2012 6 1 3 21 10.2174/187221312798889248 22022925
    [Google Scholar]
  23. Hoffman M.B. Hill D. Feldman S.R. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin. Drug Deliv. 2016 13 10 1461 1473 10.1080/17425247.2016.1188801 27164301
    [Google Scholar]
  24. Pradhan M. Alexander A. Singh M.R. Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed. Pharmacother. 2018 107 447 463 10.1016/j.biopha.2018.07.156 30103117
    [Google Scholar]
  25. Biswasroy P. Pradhan D. Kar B. Ghosh G. Rath G. Recent advance- ment in topical nanocarriers for the treatment of psoriasis. AAPS PharmSciTech 2021 22 5 164 10.1208/s12249‑021‑02057‑z 34041632
    [Google Scholar]
  26. Matsumura Y. Ananthaswamy H.N. Toxic effects of ultraviolet radiation on the skin. Toxicol. Appl. Pharmacol. 2004 195 3 298 308 10.1016/j.taap.2003.08.019 15020192
    [Google Scholar]
  27. Rahman M. Akhter S. Ahmad J. Ahmad M.Z. Beg S. Ahmad F.J. Nanomedicine-based drug targeting for psoriasis: Potentials and emerging trends in nanoscale pharmacotherapy. Expert Opin. Drug Deliv. 2015 12 4 635 652 10.1517/17425247.2015.982088 25439967
    [Google Scholar]
  28. Feldman S.R. Goffe B. Rice G. The challenge of managing psoriasis: Unmet medical needs and stakeholder perspectives. Am. Health Drug Benefits 2016 9 9 504 513 28465778
    [Google Scholar]
  29. Van De Kerkhof P.C.M. How to position antipsoriatic treatments? J. Dermatolog. Treat. 2006 17 6 325 326 10.1080/09546630601114784 17853304
    [Google Scholar]
  30. van de Kerkhof P.C.M. Reich K. Kavanaugh A. Physician perspectives in the management of psoriasis and psoriatic arthritis: Results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J. Eur. Acad. Dermatol. Venereol. 2015 29 10 2002 2010 10.1111/jdv.13150 25885420
    [Google Scholar]
  31. Doppalapudi S. Jain A. Bulbake U. Khan W. Nanotherapeutics: Emerging trends in management of psoriasis. Pharm. Nanotechnol. 2016 4 4 267 283 10.2174/2211738504666161014091932
    [Google Scholar]
  32. Sala M. Elaissari A. Fessi H. Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J. Control. Release 2016 239 182 202 10.1016/j.jconrel.2016.07.003 27381248
    [Google Scholar]
  33. Kim W.B. Jerome D. Yeung J. Diagnosis and management of psoriasis. Can. Fam. Physician 2017 63 4 278 285 28404701
    [Google Scholar]
  34. Rajagopalan M. Chatterjee M. De A. Systemic management of psoriasis patients in Indian scenario: An expert consensus. Indian Dermatol. Online J. 2021 12 5 674 682 10.4103/idoj.IDOJ_113_21 34667752
    [Google Scholar]
  35. Ogawa E. Sato Y. Minagawa A. Okuyama R. Pathogenesis of psoriasis and development of treatment. J. Dermatol. 2018 45 3 264 272 10.1111/1346‑8138.14139 29226422
    [Google Scholar]
  36. Armstrong A.W. Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA 2020 323 19 1945 1960 10.1001/jama.2020.4006 32427307
    [Google Scholar]
  37. Warren E.W. Khanderia U. Use of retinoids in the treatment of psoriasis. Clin. Pharm. 1989 8 5 344 351 2663325
    [Google Scholar]
  38. Psoriasis treatment: Coal tar. 2023 Available from:https://www.aad.org/public/diseases/psoriasis/treatment/med- ications/coal-tar
  39. Aronson J.K. Coal tar and Dithranol Meyler’s Side Effects of Drugs, The International Encyclopedia of Adverse Drug Reactions and Interactions. 16th ed Amsterdam, The Netherlands Elsevier 2016 487 489
    [Google Scholar]
  40. Rapalli V.K. Kaul V. Waghule T. Curcumin loaded nanostructured lipid carriers for enhanced skin retained topical delivery: Optimization, scale-up, in-vitro characterization and assessment of ex-vivo skin deposition. Eur. J. Pharm. Sci. 2020 152 105438 10.1016/j.ejps.2020.105438 32598913
    [Google Scholar]
  41. Pradhan M. Singh D. Murthy S.N. Singh M.R. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis. Steroids 2015 101 56 63 10.1016/j.steroids.2015.05.012 26049018
    [Google Scholar]
  42. Agrawal Y. Petkar K.C. Sawant K.K. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int. J. Pharm. 2010 401 1-2 93 102 10.1016/j.ijpharm.2010.09.007 20858539
    [Google Scholar]
  43. Agrawal Y.O. Mahajan U.B. Mahajan H.S. Ojha S. Methotrexate- loaded nanostructured lipid carrier gel alleviates imiquimodinduced psoriasis by moderating inflammation: Formulation, optimization, characterization, in-vitro and in-vivo studies. Int. J. Nanomedicine 2020 15 4763 4778 10.2147/IJN.S247007 32753865
    [Google Scholar]
  44. Puglia C. Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin. Drug Deliv. 2012 9 4 429 441 10.1517/17425247.2012.666967 22394125
    [Google Scholar]
  45. Mohd Nordin U.U. Ahmad N. Salim N. Mohd Yusof N.S. Lipid-based nanoparticles for psoriasis treatment: A review on conventional treatments, recent works, and future prospects. RSC Advances 2021 11 46 29080 29101 10.1039/D1RA06087B 35478537
    [Google Scholar]
  46. Müller R.H. Radtke M. Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002 242 1-2 121 10.1016/S0378‑5173(02)00180‑1
    [Google Scholar]
  47. Chauhan I. Yasir M. Verma M. Singh A.P. Nanostructured lipid car- riers: A groundbreaking approach for transdermal drug delivery. Adv. Pharm. Bull. 2020 10 2 150 165 10.34172/apb.2020.021 32373485
    [Google Scholar]
  48. Weber S. Zimmer A. Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art. Eur. J. Pharm. Biopharm. 2014 86 1 7 22 10.1016/j.ejpb.2013.08.013 24007657
    [Google Scholar]
  49. Patil T.S. Deshpande A.S. Nanostructured lipid carriers-based drug delivery for treating various lung diseases: A State‐of‐the‐Art Re- view. Int. J. Pharm. 2018 547 1-2 209 225 10.1016/j.ijpharm.2018.05.070 29859922
    [Google Scholar]
  50. Patil T.S. Deshpande A.S. Deshpande S. Shende P. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: Current status and futuristic need. J. Drug Target. 2019 27 1 12 27 10.1080/1061186X.2018.1455842 29561179
    [Google Scholar]
  51. Su Y.H. Fang J.Y. Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin. Drug Deliv. 2008 5 2 235 249 10.1517/17425247.5.2.235 18248321
    [Google Scholar]
  52. Goyal R. Macri L.K. Kaplan H.M. Kohn J. Nanoparticles and nanofibers for topical drug delivery. J. Control. Release 2016 240 77 92 10.1016/j.jconrel.2015.10.049 26518723
    [Google Scholar]
  53. Bouwstra J. Honeywell-Nguyen P.L. Gooris G.S. Ponec M. Structure of the skin barrier and its modulation by vesicular formulations. Prog. Lipid Res. 2003 42 1 1 36 10.1016/S0163‑7827(02)00028‑0 12467638
    [Google Scholar]
  54. Schäferkorting M. Mehnert W. Korting H. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev. 2007 59 6 427 443 10.1016/j.addr.2007.04.006 17544165
    [Google Scholar]
  55. Geusens B. Strobbe T. Bracke S. Lipid-mediated gene delivery to the skin. Eur. J. Pharm. Sci. 2011 43 4 199 211 10.1016/j.ejps.2011.04.003 21515366
    [Google Scholar]
  56. Hua S. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front. Pharmacol. 2015 6 219 10.3389/fphar.2015.00219 26483690
    [Google Scholar]
  57. Lane M.E. Skin penetration enhancers. Int. J. Pharm. 2013 447 1-2 12 21 10.1016/j.ijpharm.2013.02.040 23462366
    [Google Scholar]
  58. Potts R.O. Guy R.H. A predictive algorithm for skin permeability: The effects of molecular size and hydrogen bond activity. Pharm. Res. 1995 12 11 1628 1633 10.1023/A:1016236932339 8592661
    [Google Scholar]
  59. Knorr F. Lademann J. Patzelt A. Sterry W. Blume-Peytavi U. Vogt A. Follicular transport route – Research progress and future perspectives. Eur. J. Pharm. Biopharm. 2009 71 2 173 180 10.1016/j.ejpb.2008.11.001 19041720
    [Google Scholar]
  60. Zhai Y. Zhai G. Advances in lipid-based colloid systems as drug carrier for topic delivery. J. Control. Release 2014 193 90 99 10.1016/j.jconrel.2014.05.054 24939745
    [Google Scholar]
  61. Verma D. Verma S. Blume G. Fahr A. Particle size of liposomes influences dermal delivery of substances into skin. Int. J. Pharm. 2003 258 1-2 141 151 10.1016/S0378‑5173(03)00183‑2 12753761
    [Google Scholar]
  62. Gupta S. Bansal R. Gupta S. Jindal N. Jindal A. Nanocarriers and nanoparticles for skin care and dermatological treatments. Indian Dermatol. Online J. 2013 4 4 267 272 10.4103/2229‑5178.120635 24350003
    [Google Scholar]
  63. Saleem S. Iqubal M.K. Garg S. Ali J. Baboota S. Trends in nanotechnology-based delivery systems for dermal targeting of drugs: An enticing approach to offset psoriasis. Expert Opin. Drug Deliv. 2020 17 6 817 838 10.1080/17425247.2020.1758665 32315216
    [Google Scholar]
  64. Gupta M. Agrawal U. Vyas S.P. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Expert Opin. Drug Deliv. 2012 9 7 783 804 10.1517/17425247.2012.686490 22559240
    [Google Scholar]
  65. Jain S. Patel N. Shah M.K. Khatri P. Vora N. Recent advances in lipid-based vesicles and particulate carriers for topical and transder- mal application. J. Pharm. Sci. 2017 106 2 423 445 10.1016/j.xphs.2016.10.001 27865609
    [Google Scholar]
  66. Akhter M.H. Ahsan M.J. Rahman M. Anwar S. Rizwanullah M. Ad- vancement in nanotheranostics for effective skin cancer therapy: State of the art. Curr. Nanomed. 2020 10 2 90 104 10.2174/2468187308666181116130949
    [Google Scholar]
  67. Chuang S.Y. Lin C.H. Huang T.H. Fang J.Y. Lipid-based nanoparti- cles as a potential delivery approach in the treatment of rheumatoid arthritis. Nanomaterials 2018 8 1 42 10.3390/nano8010042 29342965
    [Google Scholar]
  68. Sala M. Diab R. Elaissari A. Fessi H. Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications. Int. J. Pharm. 2018 535 1-2 1 17 10.1016/j.ijpharm.2017.10.046 29111097
    [Google Scholar]
  69. Simoes S. Carvalheiro M. Gaspar M. Lipid-based nanocarriers for cutaneous leishmaniais and buruli ulcer management. Curr. Pharm. Des. 2017 22 43 6577 6586 10.2174/1381612822666160701083812 27396598
    [Google Scholar]
  70. Md S. Haque S. Madheswaran T. Lipid based nanocarriers system for topical delivery of photosensitizers. Drug Discov. Today 2017 22 8 1274 1283 10.1016/j.drudis.2017.04.010 28456749
    [Google Scholar]
  71. Saka R. Jain H. Kommineni N. Chella N. Khan W. Enhanced penetration and improved therapeutic efficacy of bexarotene via topical liposomal gel in imiquimod induced psoriatic plaque model in BALB/c mice. J. Drug Deliv. Sci. Technol. 2020 58 101691 10.1016/j.jddst.2020.101691
    [Google Scholar]
  72. Wadhwa S. Singh B. Sharma G. Raza K. Katare O.P. Liposomal fusidic acid as a potential delivery system: A new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv. 2016 23 4 1204 1213 10.3109/10717544.2015.1110845 26592918
    [Google Scholar]
  73. Walunj M. Doppalapudi S. Bulbake U. Khan W. Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. J. Liposome Res. 2020 30 1 68 79 10.1080/08982104.2019.1593449 30897993
    [Google Scholar]
  74. Dhavale R.P. Nadaf S.J. Bhatia M.S. Quantitative structure property relationship assisted development of Fluocinolone acetonide loaded transfersomes for targeted delivery. J. Drug Deliv. Sci. Technol. 2021 65 102758 10.1016/j.jddst.2021.102758
    [Google Scholar]
  75. Bahramizadeh M. Bahramizadeh M. Kiafar B. Development, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model. Int. J. Pharm. 2019 569 118623 10.1016/j.ijpharm.2019.118623 31419462
    [Google Scholar]
  76. Gizaway S.E. Fadel M. Mourad B. Elnaby F.E.A. Betamethasone di- propionate gel for treatment of localized plaque psoriasis. Int. J. Pharm. Pharm. Sci. 2017 9 8 173 10.22159/ijpps.2017v9i8.18571
    [Google Scholar]
  77. Pandey S.S. Shah K.M. Maulvi F.A. Topical delivery of cyclosporine loaded tailored niosomal nanocarriers for improved skin penetration and deposition in psoriasis: Optimization, ex vivo and animal studies. J. Drug Deliv. Sci. Technol. 2021 63 102441 10.1016/j.jddst.2021.102441
    [Google Scholar]
  78. Meng S. Sun L. Wang L. Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity. Colloids Surf. B Biointerfaces 2019 182 110352 10.1016/j.colsurfb.2019.110352 31306831
    [Google Scholar]
  79. Ourique A.F. Melero A. Silva C.B. Improved photostability and reduced skin permeation of tretinoin: Development of a semisolid nanomedicine. Eur. J. Pharm. Biopharm. 2011 79 1 95 101 10.1016/j.ejpb.2011.03.008 21402157
    [Google Scholar]
  80. Doppalapudi S. Jain A. Chopra D.K. Khan W. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur. J. Pharm. Sci. 2017 96 515 529 10.1016/j.ejps.2016.10.025 27777066
    [Google Scholar]
  81. Savian A.L. Rodrigues D. Weber J. Dithranol-loaded lipid-core nanocapsules improve the photostability and reduce the in vitro irritation potential of this drug. Mater. Sci. Eng. C 2015 46 69 76 10.1016/j.msec.2014.10.011 25491961
    [Google Scholar]
  82. Bodnár K. Fehér P. Ujhelyi Z. Bácskay I. Józsa L. Recent ap- proaches for the topical treatment of psoriasis using nanoparticles. Pharmaceutics 2024 16 4 449 10.3390/pharmaceutics16040449 38675110
    [Google Scholar]
  83. Fesq H. Lehmann J. Kontny A. Improved risk-benefit ratio for topical triamcinolone acetonide in TransfersomeR in comparison with equipotent cream and ointment: A randomized controlled trial. Br. J. Dermatol. 2003 149 3 611 619 10.1046/j.1365‑2133.2003.05475.x 14510997
    [Google Scholar]
  84. Scognamiglio I. De Stefano D. Campani V. Nanocarriers for topical administration of resveratrol: A comparative study. Int. J. Pharm. 2013 440 2 179 187 10.1016/j.ijpharm.2012.08.009 22909994
    [Google Scholar]
  85. Fang Y.P. Huang Y.B. Wu P.C. Tsai Y.H. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur. J. Pharm. Biopharm. 2009 73 3 391 398 10.1016/j.ejpb.2009.07.011 19660544
    [Google Scholar]
  86. Arora D. Nanda S. Quality by design driven development of resveratrol loaded ethosomal hydrogel for improved dermatological benefits via enhanced skin permeation and retention. Int. J. Pharm. 2019 567 118448 10.1016/j.ijpharm.2019.118448 31226472
    [Google Scholar]
  87. Negi P. Sharma I. Hemrajani C. Thymoquinone-loaded lipid vesicles: A promising nanomedicine for psoriasis. BMC Complement. Altern. Med. 2019 19 1 334 10.1186/s12906‑019‑2675‑5 31771651
    [Google Scholar]
  88. Abu Hashim I. Abo El-Magd N. El-Sheakh A. Hamed M. Abd El-Gawad A.E.G. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: Ex vivo–in vivo evaluation study. Int. J. Nanomedicine 2018 13 1059 1079 10.2147/IJN.S156412 29503541
    [Google Scholar]
  89. Abdelbary A.A. AbouGhaly M.H.H. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: Application of Box–Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int. J. Pharm. 2015 485 1-2 235 243 10.1016/j.ijpharm.2015.03.020 25773359
    [Google Scholar]
  90. Moghddam S.R.M. Ahad A. Aqil M. Imam S.S. Sultana Y. Formulation and optimization of niosomes for topical diacerein delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis. Mater. Sci. Eng. C 2016 69 789 797 10.1016/j.msec.2016.07.043 27612773
    [Google Scholar]
  91. Melero A. Ferreira Ourique A. Stanisçuaski Guterres S. Nanoencapsulation in lipid-core nanocapsules controls mometasone furoate skin permeability rate and its penetration to the deeper skin layers. Skin Pharmacol. Physiol. 2014 27 4 217 10.1159/000354921 24751514
    [Google Scholar]
  92. Rapalli V.K. Sharma S. Roy A. Alexander A. Singhvi G. Solid lipid nanocarriers embedded hydrogel for topical delivery of apremilast: In-vitro, ex-vivo, dermatopharmacokinetic and anti-psoriatic evaluation. J. Drug Deliv. Sci. Technol. 2021 63 102442 10.1016/j.jddst.2021.102442
    [Google Scholar]
  93. Pradhan M. Singh D. Singh M.R. Influence of selected variables on fabrication of Triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders. Artif. Cells Nanomed. Biotechnol. 2016 44 1 392 400 10.3109/21691401.2014.955105 25229831
    [Google Scholar]
  94. Ren G. Zhao Y. Preparation methods and thermal stability of calcipotriol solid lipid nanoparticles and efficacy in plaque psoriasis treatment. J. Therm. Anal. Calorim. 2021 144 6 2091 2098 10.1007/s10973‑021‑10627‑3
    [Google Scholar]
  95. Fang J.Y. Fang C.L. Liu C.H. Su Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 2008 70 2 633 640 10.1016/j.ejpb.2008.05.008 18577447
    [Google Scholar]
  96. Agrawal U. Gupta M. Vyas S.P. Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis. Artif. Cells Nanomed. Biotechnol. 2015 43 1 33 39 10.3109/21691401.2013.832683 24040836
    [Google Scholar]
  97. Tripathi P. Kumar A. Jain P.K. Patel J.R. Carbomer gel bearing meth- otrexate loaded lipid nanocontainers shows improved topical deliv- ery intended for effective management of psoriasis. Int. J. Biol. Macromol. 2018 120 1322 10.1016/j.ijbiomac.2018.08.136
    [Google Scholar]
  98. Kaur N. Sharma K. Bedi N. Topical nanostructured lipid carrier based hydrogel of mometasonefuroate for the treatment of psoriasis. Pharm. Nanotechnol. 2018 6 2 133 143 10.2174/2211738506666180523112513 29788899
    [Google Scholar]
  99. Pukale S.S. Sharma S. Dalela M. Multi-component clobetasol-loaded monolithic lipid-polymer hybrid nanoparticles ameliorate imiquimod-induced psoriasis-like skin inflammation in Swiss albino mice. Acta Biomater. 2020 115 393 409 10.1016/j.actbio.2020.08.020 32846238
    [Google Scholar]
  100. Rajitha P. Shammika P. Aiswarya S. Gopikrishnan A. Jayakumar R. Sabitha M. Chaulmoogra oil based methotrexate loaded topical nanoemulsion for the treatment of psoriasis. J. Drug Deliv. Sci. Technol. 2019 49 463 476 10.1016/j.jddst.2018.12.020
    [Google Scholar]
  101. Mittal S. Ali J. Baboota S. Enhanced anti-psoriatic activity of tacrolimus loaded nanoemulsion gel via omega 3 - Fatty acid (EPA and DHA) rich oils-fish oil and linseed oil. J. Drug Deliv. Sci. Technol. 2021 63 102458 10.1016/j.jddst.2021.102458
    [Google Scholar]
  102. Wan T. Pan J. Long Y. Dual roles of TPGS based microemulsion for tacrolimus: Enhancing the percutaneous delivery and anti-psoriatic efficacy. Int. J. Pharm. 2017 528 1-2 511 523 10.1016/j.ijpharm.2017.06.050 28629978
    [Google Scholar]
  103. Langasco R. Tanrıverdi S.T. Özer Ö. Prolonged skin retention of clobetasol propionate by bio-based microemulsions: A potential tool for scalp psoriasis treatment. Drug Dev. Ind. Pharm. 2018 44 3 398 406 10.1080/03639045.2017.1395458 29098874
    [Google Scholar]
  104. Lin Y.K. Huang Z-R. Zhuo R.Z. Fang J.Y. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomedicine 2010 5 117 128 20309398
    [Google Scholar]
  105. Viegas J.S.R. Praça F.G. Caron A.L. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. Drug Deliv. Transl. Res. 2020 10 3 646 660 10.1007/s13346‑020‑00723‑6 32060883
    [Google Scholar]
  106. Arora R. Katiyar S.S. Kushwah V. Jain S. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: A comparative study. Expert Opin. Drug Deliv. 2017 14 2 165 177 10.1080/17425247.2017.1264386 27882780
    [Google Scholar]
  107. Sonawane R. Harde H. Katariya M. Agrawal S. Jain S. Solid lipid nanoparticles-loaded topical gel containing combination drugs: An approach to offset psoriasis. Expert Opin. Drug Deliv. 2014 11 12 1833 1847 10.1517/17425247.2014.938634 25078031
    [Google Scholar]
  108. Algahtani M.S. Ahmad M.Z. Nourein I.H. Ahmad J. Co-delivery of imiquimod and curcumin by nanoemugel for improved topical de- livery and reduced psoriasis-like skin lesions. Biomolecules 2020 10 7 968 10.3390/biom10070968 32605030
    [Google Scholar]
  109. Sahu S. Katiyar S.S. Kushwah V. Jain S. Active natural oil-based nanoemulsion containing tacrolimus for synergistic antipsoriatic efficacy. Nanomedicine 2018 13 16 1985 1998 10.2217/nnm‑2018‑0135 30188761
    [Google Scholar]
  110. Parnami N. Garg T. Rath G. Goyal A.K. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif. Cells Nanomed. Biotechnol. 2014 42 6 406 412 10.3109/21691401.2013.837474 24079701
    [Google Scholar]
  111. a Chen J. Ma Y. Tao Y. Formulation and evaluation of a topical liposomal gel containing a combination of zedoary turmeric oil and tretinoin for psoriasis activity. J. Liposome Res. 2021 31 2 130 144 10.1080/08982104.2020.1748646 32223352
    [Google Scholar]
  112. b Boakye C.H.A. Patel K. Doddapaneni R. Bagde A. Marepally S. Singh M. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. J. Control. Release 2017 246 120 132 10.1016/j.jconrel.2016.05.017 27170227
    [Google Scholar]
  113. Jain A. Doppalapudi S. Domb A.J. Khan W. Tacrolimus and curcumin co-loaded liposphere gel: Synergistic combination towards management of psoriasis. J. Control. Release 2016 243 132 145 10.1016/j.jconrel.2016.10.004 27725194
    [Google Scholar]
  114. Marepally S. Boakye C.H.A. Patel A.R. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine 2014 9 14 2157 2174 10.2217/nnm.13.202 24593003
    [Google Scholar]
  115. Somagoni J. Boakye C.H.A. Godugu C. Nanomiemgel--a novel drug delivery system for topical application--in vitro and in vivo evaluation. PLoS One 2014 9 12 e115952 10.1371/journal.pone.0115952 25546392
    [Google Scholar]
  116. Jain H. Geetanjali D. Dalvi H. Bhat A. Godugu C. Srivastava S. Liposome mediated topical delivery of Ibrutinib and Curcumin as a synergistic approach to combat imiquimod induced psoriasis. J. Drug Deliv. Sci. Technol. 2022 68 103103 10.1016/j.jddst.2022.103103
    [Google Scholar]
  117. Khatoon K. Ali A. Ahmad F.J. Novel nanoemulsion gel containing triple natural bio-actives combination of curcumin, thymoquinone, and resveratrol improves psoriasis therapy: In vitro and in vivo studies. Drug Deliv. Transl. Res. 2021 11 3 1245 1260 10.1007/s13346‑020‑00852‑y 32965640
    [Google Scholar]
  118. Wang W. Shu G. Lu K. Flexible liposomal gel dual-loaded with all-trans retinoic acid and betamethasone for enhanced therapeutic efficiency of psoriasis. J. Nanobiotechnology 2020 18 1 80 10.1186/s12951‑020‑00635‑0 32448273
    [Google Scholar]
  119. Guo T. Lu J. Fan Y. TPGS assists the percutaneous administration of curcumin and glycyrrhetinic acid coloaded functionalized ethosomes for the synergistic treatment of psoriasis. Int. J. Pharm. 2021 604 120762 10.1016/j.ijpharm.2021.120762 34082000
    [Google Scholar]
  120. Pradhan M. Yadav K. Singh D. Singh M.R. Topical delivery of fluocinolone acetonide integrated NLCs and salicylic acid enriched gel: A potential and synergistic approach in the management of psoriasis. J. Drug Deliv. Sci. Technol. 2021 61 102282 10.1016/j.jddst.2020.102282
    [Google Scholar]
  121. Lebwohl M. Menter A. Koo J. Feldman S.R. Combination therapy to treat moderate to severe psoriasis. J. Am. Acad. Dermatol. 2004 50 3 416 430 10.1016/j.jaad.2002.12.002 14988684
    [Google Scholar]
  122. Gustafson C.J. Watkins C. Hix E. Feldman S.R. Combination therapy in psoriasis: An evidence-based review. Am. J. Clin. Dermatol. 2013 14 1 9 25 10.1007/s40257‑012‑0003‑7 23329077
    [Google Scholar]
  123. Nakamura M. Koo J. Safety considerations with combination therapies for psoriasis. Expert Opin. Drug Saf. 2020 19 4 489 498 10.1080/14740338.2020.1722640 31985309
    [Google Scholar]
  124. Hu C.M.J. Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012 83 8 1104 1111 10.1016/j.bcp.2012.01.008 22285912
    [Google Scholar]
  125. Qadir A. Aqil M. Ali A. Nanostructured lipidic carriers for dual drug delivery in the management of psoriasis: Systematic optimization, dermatokinetic and preclinical evaluation. J. Drug Deliv. Sci. Technol. 2020 57 101775 10.1016/j.jddst.2020.101775
    [Google Scholar]
  126. Kaur A. Katiyar S.S. Kushwah V. Jain S. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine 2017 13 4 1473 1482 10.1016/j.nano.2017.02.009 28259803
    [Google Scholar]
  127. Ferreira M. Barreiros L. Segundo M.A. Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management. Colloids Surf. B Biointerfaces 2017 159 23 29 10.1016/j.colsurfb.2017.07.080 28779637
    [Google Scholar]
  128. Ferreira M. Silva E. Barreiros L. Segundo M.A. Costa Lima S.A. Reis S. Methotrexate loaded lipid nanoparticles for topical management of skin-related diseases: Design, characterization and skin permeation potential. Int. J. Pharm. 2016 512 1 14 21 10.1016/j.ijpharm.2016.08.008 27530292
    [Google Scholar]
  129. SaraswatA. AgarwalR. KatareO.P. KaurI. KumarB. A random-ized, double‐blind, vehicle‐controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat 2007 18 1 40 5 10.1080/09546630601028729 17365266
    [Google Scholar]
  130. RamezS.A. SolimanM.M. FadelM. Methotrexate soft nanocar-rier/fractional erbium YAG laser combination for clinical treatment of plaque psoriasis. Artif Cells Nanomed Biotechnol 2018 46 sup1 996 1002 10.1080/21691401.2018.1440236
    [Google Scholar]
  131. AliM.F. SalahM. RafeaM. SalehN. Liposomal methotrexate hydrogel for treatment of localized psoriasis: Preparation, characterization and laser targeting. Med. Sci. Monit. 2008 14 12 PI66 PI74 19043379
    [Google Scholar]
  132. Nasr M. Abdel-Hamid S. Moftah N.H. Fadel M. Alyoussef A.A. Jojoba oil soft colloidal nanocarrier of a synthetic retinoid: Preparation, characterization and clinical efficacy in psoriatic patients. Curr. Drug Deliv. 2017 14 3 426 432 10.2174/1567201813666160513132321 27174314
    [Google Scholar]
  133. Sarafian G. Afshar M. Mansouri P. Asgarpanah J. Raoufinejad K. Rajabi M. Topical turmeric microemulgel in the management of plaque psoriasis: A clinical evaluation. Iran. J. Pharm. Res. 2015 14 3 865 876 26330875
    [Google Scholar]
  134. Modi C. Bharadia P. In-vitro and ex-vivo evaluation of transfersomal gel of methotrexate. Braz. J. Pharm. Sci. 2023 59 e22643 10.1590/s2175‑97902023e22643
    [Google Scholar]
  135. Qiu F, Xi L, Chen S, Zhao Y, Wang Z, Zheng Y. Celastrol niosome hydrogel has anti-inflammatory effect on skin keratinocytes and cir-culation without systemic drug exposure in psoriasis mice. Int J Na-nomedicine 2021 16 6171 82 10.2147/IJN.S323208 34511913
    [Google Scholar]
  136. Tatiya A. Patil J. Girase T. Patil M. Patel K. An overview on man- agement of psoriasis using calcipotriene and its amalgamation as nano based drug delivery system. Materials Proceedings 2023 14 1 38 10.3390/IOCN2023‑14504
    [Google Scholar]
/content/journals/cnm/10.2174/0124054615331155250128060527
Loading
Comparative Therapeutic Efficacy of Lipid-Based Nanocarriers versus Traditional Treatments for Psoriasis: A Comprehensive Review
Bentham Science Publishers ; https://doi.org/10.2174/0124054615331155250128060527
/content/journals/cnm/10.2174/0124054615331155250128060527
/content/journals/cnm/10.2174/0124054615331155250128060527
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: drug delivery ; topical therapy ; nanostructured lipid carriers ; lipid-based nanocarriers ; skin disorder ; Psoriasis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test